Dry Powder Inhaler Performance in Chronic Pulmonary Disease
Summary
Dry powder inhalers (DPIs) have become a mainstay in the management of chronic pulmonary diseases such as chronic obstructive pulmonary disease and asthma. Their performance depends on a complex interplay between device design, powder formulation and patient inhalation technique. Intrinsic resistance within the inhaler generates turbulence necessary for deagglomeration of the drug powder, while the patient’s inspiratory effort determines the actual flow rate achieved. Optimal delivery requires a balance between sufficient inspiratory flow to disperse fine particles and avoidance of excessive flow that may deposit medication in central airways. Recent work has addressed clinical characteristics that influence inhaler efficacy, novel methods for real-time monitoring of lung deposition and the impact of device misuse on emitted dose and particle size distribution. Continued refinement of inhaler resistance profiles, powder engineering and patient training offer the potential to personalise therapy and improve health outcomes on a global scale.
Research from Nature Portfolio
Investigations into patient inspiratory capacity have revealed distinct clinical profiles associated with different peak inspiratory flow rates. A study of chronic obstructive pulmonary disease patients identified a subgroup with superoptimal inspiratory flow who exhibited fewer comorbidities, a higher body mass index and reduced exacerbation frequency, suggesting that strong inspiratory effort may confer a protective effect. Complementing this, an earlier analysis of inhalation performance across inhaler resistances uncovered a substantial proportion of patients with either suboptimal or excessive peak flows. While true insufficiency was rare, excessive flow against low-resistance devices was commonplace, irrespective of age or disease stage. These findings underline the importance of matching device resistance to individual patient capacity and of regularly monitoring inspiratory flow to optimise drug delivery.
Dry Powder Inhaler Performance in Chronic Pulmonary Disease publication trend
The graph below shows the total number of articles in dry powder inhaler performance in chronic pulmonary disease across all publications each year (not limited to Nature Index journals).
Technical terms
Dry powder inhaler (DPI): A breath-activated device that delivers medication as a dry powder formulation, relying on patient inspiratory effort to disperse the drug for inhalation.
Peak inspiratory flow rate (PIFR): The maximum airflow achieved by the patient during inhalation, critical for effective powder deaggregation and drug delivery.
Aerodynamic particle size distribution: The range and proportion of particle sizes in an aerosol, which determines regional lung deposition and therapeutic effect.
Fine particle fraction (FPF): The percentage of emitted dose composed of particles below a specified aerodynamic diameter (typically <5 µm), correlating with deep lung deposition.
References
- Dry powder inhalers and the right things to remember: a concept review. Multidisciplinary Respiratory Medicine (2015).
- Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory flow rate. Scientific Reports (2024).
- Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease. Scientific Reports (2020).
- The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study. PLOS Medicine (2025).
- The impact of possible improper use on the performance in vitro of NEXThaler in comparison with Ellipta inhaler. European Journal of Pharmaceutical Sciences (2023).
- Real-Time Particle Emission Monitoring for the Non-Invasive Prediction of Lung Deposition via a Dry Powder Inhaler. AAPS PharmSciTech (2024).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.